{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:01:58Z","timestamp":1787688118057,"version":"build-2784847793"},"reference-count":39,"publisher":"IMR Press","issue":"12","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Background: Alcohol septal ablation (ASA) has been more commonly applied in medical refractory hypertrophic obstructive cardiomyopathy (HOCM) compared with septal myectomy (SM), however its potential to create a proarrhythmic substrate is increased. Methods: A systematic search was performed in PubMed, EMBASE, Web of Science, and the Cochrane Library from inception to October 2020. Fixed or random effects models were used to estimate the risk ratios (RR) for ventricular arrhythmia events or other outcomes between the SM and ASA cohorts. Results: Twenty studies with 8025 patients were included. Pool analysis showed that the incidence of ventricular tachycardia (VT)\/ventricular fibrillation (VF), which included appropriate implantable cardioverter defibrillator (ICD) intervention, was significantly higher in the ASA cohort than that in the SM cohort (ASA vs SM: 10% (345\/3312) vs 5% (161\/3227) (RR = 1.98, 95% CI (confidence interval), 1.65\u20132.37; p &lt; 0.00001, I2 = 0%). In both groups, more than 90% of VT\/VF events occurred in the early phase (during the procedure, during hospitalization or within 30 days after the procedure) (ASA: 94.20%; SM: 94.41%). Further subgroup analysis also showed that the ASA group had a higher incidence of VT\/VF in both the early phase (RR = 1.94, 95% CI, 1.61\u20132.33; p &lt; 0.0001, I2 = 0%) and the late phase (RR = 2.80, 95% CI, 1.00\u20137.89; p = 0.05, I2 = 33%). Furthermore, although the risks of sudden cardiac death (SCD) were similar between the ASA and SM groups, a higher incidence of sudden cardiac arrest (SCA), which included SCD and resuscitated SCA, was observed in the ASA group (RR = 2.30, 95% CI, 1.35\u20133.94; p = 0.002, I2 = 0%). Conclusions: In patients with HOCM, those who received ASA showed a higher incidence of VF\/VT and SCD combined with resuscitated SCA. The majority of VT\/VF occurred in the early phase.<\/jats:p>","DOI":"10.31083\/j.rcm2312391","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:27:52Z","timestamp":1669940872000},"source":"Crossref","is-referenced-by-count":6,"title":["The Risk of Ventricular Arrhythmias between Alcohol Septal Ablation and Septal Myectomy in Hypertrophic Cardiomyopathy: A Meta-Analysis on Septal Reduction Therapy"],"prefix":"10.31083","volume":"23","author":[{"given":"Wei","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, 510080 Guangzhou, Guangdong, China"},{"name":"Department of Medicine College, Sun Yat-sen University, 510080 Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghui","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, 510080 Guangzhou, Guangdong, China"},{"name":"Department of Medicine College, Sun Yat-sen University, 510080 Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"first","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, 510080 Guangzhou, Guangdong, China"},{"name":"Department of Medicine College, Sun Yat-sen University, 510080 Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxuan","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, 510080 Guangzhou, Guangdong, China"},{"name":"Department of Medicine College, Sun Yat-sen University, 510080 Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Su","sequence":"first","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, 510080 Guangzhou, Guangdong, China"},{"name":"Department of Medicine College, Sun Yat-sen University, 510080 Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, 510080 Guangzhou, Guangdong, China"},{"name":"Department of Medicine College, Sun Yat-sen University, 510080 Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichun","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, 510080 Guangzhou, Guangdong, China"},{"name":"Department of Medicine College, Sun Yat-sen University, 510080 Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 124: 2761\u20132796.","DOI":"10.1161\/CIR.0b013e318223e230"},{"key":"ref2","unstructured":"Sherrid MV. Pharmacologic Therapy of Hypertrophic Cardiomyopathy. Current Cardiology Reviews. 2015. (in press)"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Dimitrow PP, Rajtar-Salwa R. Obstructive Form of Hypertrophic Cardiomyopathy-Left Ventricular Outflow Tract Gradient: Novel Methods of Provocation, Monitoring of Biomarkers, and Recent Advances in the Treatment. BioMed Research International. 2016; 2016: 1575130.","DOI":"10.1155\/2016\/1575130"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). European Heart Journal. 2014; 35: 2733\u20132739.","DOI":"10.1093\/eurheartj\/ehu284"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Kim LK, Swaminathan RV, Looser P, Minutello RM, Wong SC, Bergman G, et al. Hospital Volume Outcomes after Septal Myectomy and Alcohol Septal Ablation for Treatment of Obstructive Hypertrophic Cardiomyopathy: US Nationwide Inpatient Database, 2003\u20132011. JAMA Cardiology. 2016; 1: 324\u2013332.","DOI":"10.1001\/jamacardio.2016.0252"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Cuoco FA, Spencer WH, Fernandes VL, Nielsen CD, Nagueh S, Sturdivant JL, et al. Implantable Cardioverter-Defibrillator Therapy for Primary Prevention of Sudden Death after Alcohol Septal Ablation of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. 2008; 52: 1718\u20131723.","DOI":"10.1016\/j.jacc.2008.07.061"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Maron BJ. Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. The Lancet. 2000; 355: 425\u2013426.","DOI":"10.1016\/S0140-6736(99)00444-4"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Noseworthy PA, Rosenberg MA, Fifer MA, Palacios IF, Lowry PA, Ruskin JN, et al. Ventricular Arrhythmia Following Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy. The American Journal of Cardiology. 2009; 104: 128\u2013132.","DOI":"10.1016\/j.amjcard.2009.02.056"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Batzner A, Pfeiffer B, Neugebauer A, Aicha D, Blank C, Seggewiss H. Survival after Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy. Journal of the American College of Cardiology. 2018; 72: 3087\u20133094.","DOI":"10.1016\/j.jacc.2018.09.064"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Nguyen A, Schaff HV, Hang D, Nishimura RA, Geske JB, Dearani JA, et al. Surgical Myectomy Versus Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy: A Propensity Score-Matched Cohort. The Journal of Thoracic and Cardiovascular Surgery. 2019; 157: 306\u2013315.","DOI":"10.1016\/j.jtcvs.2018.08.062"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Osman M, Kheiri B, Osman K, Barbarawi M, Alhamoud H, Alqahtani F, et al. Alcohol Septal Ablation vs Myectomy for Symptomatic Hypertrophic Obstructive Cardiomyopathy: Systematic Review and Meta\u2010Analysis. Clinical Cardiology. 2019; 42: 190\u2013197.","DOI":"10.1002\/clc.23113"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Byty\u00e7i I, Nistri S, M\u00f6rner S, Henein MY. Alcohol Septal Ablation versus Septal Myectomy Treatment of Obstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2020; 9: 3062.","DOI":"10.3390\/jcm9103062"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Lemor A, Villablanca PA, Hosseini Dehkordi SH, Mand R, Hernandez GA, Jain T, et al. Comparison of Outcomes of Alcohol Septal Ablation or Septal Myectomy for Hypertrophic Cardiomyopathy in Patients \u226465 Years Versus >65 Years. The American Journal of Cardiology. 2020; 127: 128\u2013134.","DOI":"10.1016\/j.amjcard.2020.04.018"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Afanasyev AV, Bogachev-Prokophiev AV, Kashtanov MG, Astapov DA, Zalesov AS, Budagaev SA, et al. Myectomy versus alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. Interactive CardioVascular and Thoracic Surgery. 2020; 31: 158\u2013165.","DOI":"10.1093\/icvts\/ivaa075"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Kimmelstiel C, Zisa DC, Kuttab JS, Wells S, Udelson JE, Wessler BS, et al. Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy is Associated with Excellent Clinical Outcomes. Circulation: Cardiovascular Interventions. 2019; 12: e007673.","DOI":"10.1161\/CIRCINTERVENTIONS.118.007673"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Guo H, Li J, Jiang T, Ren C, Dai J, Zhou Y, et al. Comparison of Clinical Effects between Percutaneous Transluminal Septal Myocardial Ablation and Modified Morrow Septal Myectomy on Patients with Hypertrophic Cardiomyopathy. Chinese Medical Journal. 2018; 131: 527\u2013531.","DOI":"10.4103\/0366-6999.226075"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Cavigli L, Fumagalli C, Maurizi N, Rossi A, Arretini A, Targetti M, et al. Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy. International Journal of Cardiology. 2018; 273: 155\u2013161.","DOI":"10.1016\/j.ijcard.2018.09.004"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Yang Y, Fan C, Yuan J, Wang S, Song Y, Qiao S, et al. Effectiveness of Alcohol Septal Ablation Versus Transaortic Extended Myectomy in Hypertrophic Cardiomyopathy with Midventricular Obstruction. Journal of Interventional Cardiology. 2016; 29: 619\u2013627.","DOI":"10.1111\/joic.12331"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Sedehi D, Finocchiaro G, Tibayan Y, Chi J, Pavlovic A, Kim YM, et al. Long-term outcomes of septal reduction for obstructive hypertrophic cardiomyopathy. Journal of Cardiology. 2015; 66: 57\u201362.","DOI":"10.1016\/j.jjcc.2014.08.010"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Vriesendorp PA, Liebregts M, Steggerda RC, Schinkel AFL, Willems R, ten Cate FJ, et al. Long-Term Outcomes after Medical and Invasive Treatment in Patients with Hypertrophic Cardiomyopathy. JACC: Heart Failure. 2014; 2: 630\u2013636.","DOI":"10.1016\/j.jchf.2014.06.012"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Steggerda RC, Damman K, Balt JC, Liebregts M, ten Berg JM, van den Berg MP. Periprocedural Complications and Long-Term Outcome after Alcohol Septal Ablation Versus Surgical Myectomy in Hypertrophic Obstructive Cardiomyopathy: a single-center experience. JACC: Cardiovascular Interventions. 2014; 7: 1227\u20131234.","DOI":"10.1016\/j.jcin.2014.05.023"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Samardhi H, Walters DL, Raffel C, Rateesh S, Harley C, Burstow D, et al. The long-term outcomes of transcoronary ablation of septal hypertrophy compared to surgical myectomy in patients with symptomatic hypertrophic obstructive cardiomyopathy. Catheterization and Cardiovascular Interventions. 2014; 83: 270\u2013277.","DOI":"10.1002\/ccd.25134"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Sorajja P, Ommen SR, Holmes DR, Dearani JA, Rihal CS, Gersh BJ, et al. Survival after Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy. Circulation. 2012; 126: 2374\u20132380.","DOI":"10.1161\/CIRCULATIONAHA.111.076257"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"ten Cate FJ, Soliman OII, Michels M, Theuns DAMJ, de Jong PL, Geleijnse ML, et al. Long-Term Outcome of Alcohol Septal Ablation in Patients with Obstructive Hypertrophic Cardiomyopathy: a word of caution. Circulation: Heart Failure. 2010; 3: 362\u2013369.","DOI":"10.1161\/CIRCHEARTFAILURE.109.862359"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Valeti US, Nishimura RA, Holmes DR, Araoz PA, Glockner JF, Breen JF, et al. Comparison of Surgical Septal Myectomy and Alcohol Septal Ablation with Cardiac Magnetic Resonance Imaging in Patients with Hypertrophic Obstructive Cardiomyopathy. Journal of the American College of Cardiology. 2007; 49: 350\u2013357.","DOI":"10.1016\/j.jacc.2006.08.055"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"van der Lee C, ten Cate FJ, Geleijnse ML, Kofflard MJ, Pedone C, van Herwerden LA, et al. Percutaneous Versus Surgical Treatment for Patients with Hypertrophic Obstructive Cardiomyopathy and Enlarged Anterior Mitral Valve Leaflets. Circulation. 2005; 112: 482\u2013488.","DOI":"10.1161\/CIRCULATIONAHA.104.508309"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Ralph-Edwards A, Woo A, McCrindle BW, Shapero JL, Schwartz L, Rakowski H, et al. Hypertrophic obstructive cardiomyopathy: Comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. The Journal of Thoracic and Cardiovascular Surgery. 2005; 129: 351\u2013358.","DOI":"10.1016\/j.jtcvs.2004.08.047"},{"key":"ref28","unstructured":"Jiang TY, Wu XS, Lu Q, Meng X, Jia CQ, Zhang Y. Transcoronary ablation of septal hypertrophy compared with surgery in the treatment of hypertrophic obstructive cardiomyopathy. China Medical Journal. 2004; 117: 296\u2013298."},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Firoozi S, Elliott PM, Sharma S, Murday A, Brecker SJ, Hamid MS, et al. Septal Myotomy-Myectomy and Transcoronary Septal Alcohol Ablation in Hypertrophic Obstructive Cardiomyopathy. A Comparison of Clinical, Haemodynamic and Exercise Outcomes. European Heart Journal. 2002; 23: 1617\u20131624.","DOI":"10.1053\/euhj.2002.3285"},{"key":"ref30","unstructured":"Qin JX, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. Journal of the American College of Cardiology. 2001; 38: 1994\u20132000."},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. Journal of the American College of Cardiology. 2001; 38: 1701\u20131706.","DOI":"10.1016\/S0735-1097(01)01614-X"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Gorenek B, Blomstr\u00f6m Lundqvist C, Brugada Terradellas J, Camm AJ, Hindricks G, Huber K, et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace. 2014; 16: 1655\u20131673.","DOI":"10.1093\/europace\/euu208"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Singh K, Qutub M, Carson K, Hibbert B, Glover C. A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy. Catheterization and Cardiovascular Interventions. 2016; 88: 107\u2013115.","DOI":"10.1002\/ccd.26293"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA\/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020; 142: e533\u2013e557.","DOI":"10.1161\/CIR.0000000000000938"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Balt JC, Wijffels MCEF, Boersma LVA, Wever EFD, ten Berg JM. Continuous rhythm monitoring for ventricular arrhythmias after alcohol septal ablation for hypertrophic cardiomyopathy. Heart. 2014; 100: 1865\u20131870.","DOI":"10.1136\/heartjnl-2014-305593"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Maron BJ, Shen W, Link MS, Epstein AE, Almquist AK, Daubert JP, et al. Efficacy of Implantable Cardioverter-Defibrillators for the Prevention of Sudden Death in Patients with Hypertrophic Cardiomyopathy. New England Journal of Medicine. 2000; 342: 365\u2013373.","DOI":"10.1056\/NEJM200002103420601"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"McGregor JB, Rahman A, Rosanio S, Ware D, Birnbaum Y, Saeed M. Monomorphic Ventricular Tachycardia: a Late Complication of Percutaneous Alcohol Septal Ablation for Hypertrophic Cardiomyopathy. The American Journal of the Medical Sciences. 2004; 328: 185\u2013188.","DOI":"10.1097\/00000441-200409000-00011"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"McLeod CJ, Ommen SR, Ackerman MJ, Weivoda PL, Shen WK, Dearani JA, et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. European Heart Journal. 2007; 28: 2583\u20132588.","DOI":"10.1093\/eurheartj\/ehm117"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Liebregts M, Vriesendorp PA, Mahmoodi BK, Schinkel AF, Michels M, ten Berg JM. A Systematic Review and Meta-Analysis of Long-Term Outcomes After Septal Reduction Therapy in Patients with Hypertrophic Cardiomyopathy. JACC: Heart Fail. 2015; 3: 896\u2013905.","DOI":"10.1016\/j.jchf.2015.06.011"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/23\/12\/10.31083\/j.rcm2312391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T13:16:03Z","timestamp":1732713363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/23\/12\/10.31083\/j.rcm2312391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022]]}},"alternative-id":["S1530-6550(22)00741-4"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm2312391","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]},"article-number":"391"}}